Optimizing Patient-Clinician Communication
This CME-accredited CME Snapshot™ educational series, Breathing Life Into COPD Management: Ongoing Monitoring, Pulmonary Rehabilitation, and Individualized Care, is intended for primary care clinicians and other health care providers involved in the ongoing management of patients with chronic obstructive pulmonary disease (COPD). Within each focused activity, an expert pulmonologist and a primary care educator discuss best practices for a specific aspect of managing patients with COPD, including monitoring the disease course over time, maximizing patient function, and individualizing treatment regimens. One activity also addresses patients’ perspectives by incorporating patient-clinician interactions and insights into disease burdens, challenges to good long-term outcomes, and shared decision-making.
This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with chronic obstructive pulmonary disease (COPD).
Upon completion of this activity, participants will be better able to do the following:
- Communicate with patients and their caregivers about the need for exacerbation action plans, treatment adherence, and open dialogue on COPD symptoms and functional status
Barry J. Make, MD, FACP, FCCP, FACVPR
Barbara P. Yawn, MD, MSc, FAAFP
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Name of Faculty or Presenter|
Relationship Identified With:
Barry J. Make, MD
Consultant/Advisor: AstraZeneca; Boehringer Ingelheim GmbH; GlaxoSmithKline plc; Spiration, Inc; Sunovian Pharmaceuticals Inc.; Theravance Biopharma; Verona Pharma plc
Grant/Research Support: AstraZeneca
Speakers’ Bureau: AstraZeneca; Boehringer Ingelheim GmbH; GlaxoSmithKline plc; Verona Pharma plc
Barbara P. Yawn, MD, MSc, FAAFP
Consultant/Advisor: AstraZeneca; GlaxoSmithKline plc
Employment Affiliation: Editor-in-Chief, Respiratory Medicine Case Reports
Non-faculty: Rose O’Connor, PhD; Jim Kappler, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouses/life partners have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from AstraZeneca.
Jointly provided by the Elsevier Office of Continuing Medical Education, American Association of Nurse Practitioners, and Integritas Communications.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Integritas Communications. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AANP CREDIT (NURSES)
This activity is approved for 0.25 contact hour(s) of continuing education by the American Association of Nurse Practitioners. Activity ID 18053198. This activity was planned in accordance with AANP CE Standards and Policies.
CME Inquiries/Special Needs
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, American Association of Nurse Practitioners, Integritas Communications, and AstraZeneca do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 0.25 AANP
- 0.25 AMA PRA Category 1 Credit(s)™
- 0.25 Non-physician